Grünenthal Meds was founded in August 2023, as a result of a Joint Venture Partnership between Grünenthal GmbH and Kyowa Kirin. Based in the UK, our responsibility involves overseeing a collection of 13 medications spanning six primary therapeutic categories, such as relieving cancer pain, addressing constipation, and promoting bone health. Leveraging a network of subsidiaries and strategic allies, we aim to deliver these essential products to patients worldwide.